Capricor Therapeutics Files 8-K on Financial Condition
Ticker: CAPR · Form: 8-K · Filed: Feb 29, 2024 · CIK: 1133869
| Field | Detail |
|---|---|
| Company | Capricor Therapeutics, Inc. (CAPR) |
| Form Type | 8-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, corporate-filing
TL;DR
**Capricor Therapeutics just dropped an 8-K on its financials, giving us a peek into their latest operational health.**
AI Summary
CAPRICOR THERAPEUTICS, INC. filed an 8-K on February 29, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing indicates the company's current address is 10865 Road to the Cure, Suite 150, San Diego, California, and its state of incorporation is Delaware. This report was filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on Capricor Therapeutics' financial status and operations, offering transparency to investors and the market regarding its current health.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate adverse events.
Key Players & Entities
- CAPRICOR THERAPEUTICS, INC. (company) — Registrant
- February 29, 2024 (date) — Date of earliest event reported
- Delaware (location) — State of incorporation
- 001-34058 (other) — Commission File Number
- 10865 Road to the Cure, Suite 150, San Diego, California (location) — Business address
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 29, 2024.
What items were reported in this 8-K filing by CAPRICOR THERAPEUTICS, INC.?
The filing reported on Results of Operations and Financial Condition, and Financial Statements and Exhibits.
Where is CAPRICOR THERAPEUTICS, INC. incorporated?
CAPRICOR THERAPEUTICS, INC. is incorporated in Delaware.
What is the Commission File Number for CAPRICOR THERAPEUTICS, INC.?
The Commission File Number is 001-34058.
What is the current business address listed for CAPRICOR THERAPEUTICS, INC.?
The current business address is 10865 Road to the Cure, Suite 150, San Diego, California.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-02-29 16:06:15
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M
Filing Documents
- capr-20240229x8k.htm (8-K) — 37KB
- capr-20240229xex99d1.htm (EX-99.1) — 168KB
- capr-20240229xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-002183.txt ( ) — 342KB
- capr-20240229.xsd (EX-101.SCH) — 3KB
- capr-20240229_lab.xml (EX-101.LAB) — 15KB
- capr-20240229_pre.xml (EX-101.PRE) — 9KB
- capr-20240229x8k_htm.xml (XML) — 5KB
02
Item 2.02 Results of Operations and Financial Condition. On February 29, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the quarter and full year ended December 31, 2023. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company's filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, titled "Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update" dated February 29, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: February 29, 2024 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3